Matches in SemOpenAlex for { <https://semopenalex.org/work/W3030051515> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W3030051515 endingPage "4" @default.
- W3030051515 startingPage "1" @default.
- W3030051515 abstract "Objective To observe the therapeutic effects,cosmetic results,and toxicities of central hypofractionated three-dimensional radiotherapy for patients with early-stage breast cancer after breastconserving surgery.Methods From February 2009 to February 2010,45 patients with pTis-2N0-1 M0 breast cancer after breast-conserving surgery were enrolled in the trial.Three-dimensional conformal radiotherapy or simplified intensity-modulated radiotherapy was applied to each patient.The hypofractionated radiotherapy schedule was 43.5 Gy/15 fractions/3 weeks to the whole breast,with a boost of 8.7 Gy/3 fractions/3 days to the tumor bed.The dose was 2.9 Gy per fraction;the total course of treatment was 24 days.Thirty-three patients received chemotherapy,including neoadjuvant chemotherapy in 2 patients and postoperative adjuvant chemotherapy in 31 patients.Locoregional control and overall survival were calculated by Kaplan-Meier method.Results The follow-up rate was 100％.The 2-year locoregional control and overall survival were both 100％,and one patient had a single bone metastasis.Of the patients,1 developed grade 2 breast edema,6 developed grade 2 breast fibrosis,1 developed grade 2 upper extremity edema,4 developed grade 2 radiation dermatitis,5 developed grade 1 radiation pneumonitis,and 2 developed grade 2 radiation pneumonitis.Compared with the conventional fractionated radiotherapy for the patients with early-stage breast cancer after breast-conserving surgery,the hypofractionated three-dimensional radiotherapy had the number of fractions decreased from 30 to 18,course of treatment shortened from 40 days to 24 days,and the cost cut from ￥ 30450 to ￥ 19770.Conclusions The central hypofractionated three-dimensional radiotherapy for the patients with early-stage breast cancer after breast-conserving surgery have good therapeutic effects and cosmetic results and acceptable toxicities,as well as significantly reduced time and cost of treatment.Key words: Breast neoplasms/surgery ; Surgery, breast-conserving surgery; Breast neoplasms/radiotherapy; Radiotherapy, hypofractionation; Treatment outcome" @default.
- W3030051515 created "2020-06-05" @default.
- W3030051515 creator A5008878144 @default.
- W3030051515 creator A5027776467 @default.
- W3030051515 creator A5079018778 @default.
- W3030051515 creator A5082419716 @default.
- W3030051515 creator A5083110250 @default.
- W3030051515 creator A5083717984 @default.
- W3030051515 creator A5084229837 @default.
- W3030051515 date "2013-01-15" @default.
- W3030051515 modified "2023-09-23" @default.
- W3030051515 title "Phase II clinical trial of central hypofractionated three-dimensional radiotherapy for patients with early-stage breast cancer after breast-conserving surgery" @default.
- W3030051515 doi "https://doi.org/10.3760/cma.j.issn.1004-4221.2013.01.001" @default.
- W3030051515 hasPublicationYear "2013" @default.
- W3030051515 type Work @default.
- W3030051515 sameAs 3030051515 @default.
- W3030051515 citedByCount "0" @default.
- W3030051515 crossrefType "journal-article" @default.
- W3030051515 hasAuthorship W3030051515A5008878144 @default.
- W3030051515 hasAuthorship W3030051515A5027776467 @default.
- W3030051515 hasAuthorship W3030051515A5079018778 @default.
- W3030051515 hasAuthorship W3030051515A5082419716 @default.
- W3030051515 hasAuthorship W3030051515A5083110250 @default.
- W3030051515 hasAuthorship W3030051515A5083717984 @default.
- W3030051515 hasAuthorship W3030051515A5084229837 @default.
- W3030051515 hasConcept C121608353 @default.
- W3030051515 hasConcept C126322002 @default.
- W3030051515 hasConcept C141071460 @default.
- W3030051515 hasConcept C146357865 @default.
- W3030051515 hasConcept C151730666 @default.
- W3030051515 hasConcept C2776694085 @default.
- W3030051515 hasConcept C2777714996 @default.
- W3030051515 hasConcept C2777757722 @default.
- W3030051515 hasConcept C2779524853 @default.
- W3030051515 hasConcept C2781467025 @default.
- W3030051515 hasConcept C509974204 @default.
- W3030051515 hasConcept C530470458 @default.
- W3030051515 hasConcept C71924100 @default.
- W3030051515 hasConcept C86803240 @default.
- W3030051515 hasConceptScore W3030051515C121608353 @default.
- W3030051515 hasConceptScore W3030051515C126322002 @default.
- W3030051515 hasConceptScore W3030051515C141071460 @default.
- W3030051515 hasConceptScore W3030051515C146357865 @default.
- W3030051515 hasConceptScore W3030051515C151730666 @default.
- W3030051515 hasConceptScore W3030051515C2776694085 @default.
- W3030051515 hasConceptScore W3030051515C2777714996 @default.
- W3030051515 hasConceptScore W3030051515C2777757722 @default.
- W3030051515 hasConceptScore W3030051515C2779524853 @default.
- W3030051515 hasConceptScore W3030051515C2781467025 @default.
- W3030051515 hasConceptScore W3030051515C509974204 @default.
- W3030051515 hasConceptScore W3030051515C530470458 @default.
- W3030051515 hasConceptScore W3030051515C71924100 @default.
- W3030051515 hasConceptScore W3030051515C86803240 @default.
- W3030051515 hasIssue "01" @default.
- W3030051515 hasLocation W30300515151 @default.
- W3030051515 hasOpenAccess W3030051515 @default.
- W3030051515 hasPrimaryLocation W30300515151 @default.
- W3030051515 hasVolume "22" @default.
- W3030051515 isParatext "false" @default.
- W3030051515 isRetracted "false" @default.
- W3030051515 magId "3030051515" @default.
- W3030051515 workType "article" @default.